Rosiglitazone improves insulin sensitivity and baroreflex gain in rats with diet-induced obesity.


Obesity decreases baroreflex gain (BRG); however, the mechanisms are unknown. We tested the hypothesis that impaired BRG is related to the concurrent insulin resistance, and, therefore, BRG would be improved after treatment with the insulin-sensitizing drug rosiglitazone. Male rats fed a high-fat diet diverged into obesity-prone (OP) and obesity-resistant… (More)
DOI: 10.1124/jpet.112.194738

10 Figures and Tables


  • Presentations referencing similar topics